ArticleJournal of neurology2026
Ocrelizumab versus ofatumumab efficacy and safety after natalizumab discontinuation in multiple sclerosis: a retrospective real-world comparison.
Veronica Marino et al.PubMed ↗Publisher ↗
No numbers read from the abstract.